ライフサイエンスコーパス: NDV

1 NDV grown in RCA-expressing cells was resistant to compl

2 NDV HN has two sialic acid binding sites: site I, which

3 NDV infection (which induces alpha interferon) had the s

4 NDV's selective replication in tumor cells has been prev

5 NDV-3 induced increases in CD3+ T-cell and neutrophil in

6 NDV-HA was administered to African green monkeys in two

7 NDV-infected cells also upregulated several genes not pr

8 solates from this outbreak (NDV-Belize-3/08, NDV-Belize-4/08, and NDV-Belize-12/08) were assessed by

9 Avian paramyxovirus type 1, NDV, has been an attractive oncolytic agent for cancer v

10 en/DominicanRepublic(JuanLopez)/499-31/2008 (NDV-DR499-31/08), and the fusion proteins of three other

11 In this study, 27 NDV isolates collected from apparently healthy chickens

12 In addition, NDV infection tended to lower the variance in AI among D

13 Here we developed additional NDV-vectored vaccines expressing either HPAIV HA in whic

14 and is a promising vaccine candidate against NDV strains circulating in Indonesia.

15 3 alone can provide cross-protection against NDV challenge.

16 lent vaccine vector that can be used against NDV and other poultry pathogens.

17 Although all NDV isolates characterized to date belong to a single se

18 Compared with adjuvant alone, NDV-3 reduced abscess progression, severity, and MRSA de

19 Although NDV vaccines exist, there are frequent reports of outbre

20 Although NDV-Peru/08 is a genetically distinct virus, pathogenesi

21 ymerase (L) genes in a complete genome of an NDV isolate from this geographical region.

22 tial environmental and economic impact of an NDV outbreak have precluded its clinical development.

23 We showed that a regimen consisting of an NDV prime followed by a protein boost elicited stronger

24 break (NDV-Belize-3/08, NDV-Belize-4/08, and NDV-Belize-12/08) were assessed by genomic analysis and

25 ficant enhancement of oncolytic activity and NDV replication.

26 with rLS/AMPV-C F&G induced both AMPV-C and NDV-specific antibody responses, and provided significan

27 as having NiV G-derived globular domains and NDV HN-derived stalks, transmembranes, and cytoplasmic t

28 disease virus (NDV)-vectored H7 (NDV-H7) and NDV-H5 vaccines are able to induce antibodies with high

29 e show that MORC3 is induced by both IFN and NDV infection in PVK cells but is not induced by either

30 nferred complete protection against ILTV and NDV challenge.

31 , when L2 cells were coinfected with MHV and NDV in the presence of IFN-beta, NDV, but not MHV, repli

32 ree vaccine viruses [NDV/HA, NDV/HA(RV), and NDV/NA] were administered separately to groups of Africa

33 ntaining a recombinant glycoprotein antigen (NDV-3) in mouse skin and skin structure infection (SSSI)

34 Thus, needle-free, highly attenuated NDV-vectored vaccines expressing either HPAIV HA, HA(RV)

35 Current live attenuated NDV vaccines are not fully satisfactory.

36 potential to generate better live attenuated NDV vaccines.

37 Each genomic segment is flanked by authentic NDV 3' and 5' noncoding termini allowing for efficient r

38 farms despite the existence of high-average NDV-specific antibody titers (>4.75 log2).

39 exchanged individually between an avirulent NDV strain, LaSota, and an intermediate virulent NDV str

40 ith MHV and NDV in the presence of IFN-beta, NDV, but not MHV, replication was inhibited.

41 alysis of the evolutionary distances between NDV-Peru/08 and other isolates representing established

42 equired the induction of IL-17A and IL-22 by NDV-3.

43 cted toward increasing antigen expression by NDV result in enhanced immunogenicity and vaccine effica

44 for enhanced expression of a foreign gene by NDV.

45 ) and ERdj5, in cell-cell fusion mediated by NDV glycoproteins.

46 t augmentation of innate immune responses by NDV results in selective oncolysis and offer a novel and

47 In 4-week-old chickens, NDV-DR499-31/08 behaved as a velogenic viscerotropic str

48 In 4-week-old SPF chickens, NDV-Belize-3/08 behaved as a typical velogenic viscerotr

49 Evaluations of these chimeric NDVs demonstrated that the thermostability of NDV was de

50 Also, PSA-cleavable NDV failed to replicate in chicken embryos, indicating n

51 Systemically delivered NDV fails to reach solid tumors in therapeutic concentra

52 ot belong to any of the previously described NDV genotypes.

53 miological surveillance strategies to detect NDV in wild-bird species and commercial poultry.

54 versity has been described between different NDV isolates.

55 We compared two different NDV vectors, a conventional rNDV vector and a modified r

56 (GFP) gene flanked by 5' and 3' UTRs of each NDV gene was individually expressed by recombinant NDVs.

57 the F and HN proteins required for efficient NDV infection and their role in avian pathogenicity.

58 and other isolates representing established NDV genotypes revealed the existence of large genomic an

59 thiols are present in cell surface-expressed NDV F protein and that blocking the production of free t

60 ng the existence of an unknown reservoir for NDV.

61 reduced levels compared to what was seen for NDV-BC.

62 ew mechanism for cancer cell specificity for NDV, making it an attractive anticancer agent for chemor

63 Substitutions for NDV HN stalk residues A89, L90, and L94 block fusion by

64 ta/46 vaccine conferred full protection from NDV-Peru/08-induced clinical disease and mortality.

65 lope afforded complement resistance, we grew NDV in CHO cells stably transfected with CD46 or HeLa ce

66 t Newcastle disease virus (NDV)-vectored H7 (NDV-H7) and NDV-H5 vaccines are able to induce antibodie

67 The three vaccine viruses [NDV/HA, NDV/HA(RV), and NDV/NA] were administered separately to

68 the finding that reciprocal chimeras having NDV HN-derived heads and NiV G-derived stalks, transmemb

69 virus (NDV) expressing the MV hemagglutinin (NDV-H).

70 This is the first description of a class II NDV strain with a genome of 15,198 nt and a 6-nt insert

71 us is classified in genotype VII of class II NDV, which is genetically distinct from the commercial v

72 indings can have significant applications in NDV vaccine development.

73 le of the internal proteins (N, P, and L) in NDV virulence by using a chimeric reverse-genetics appro

74 antiviral pathways are highly upregulated in NDV-infected PVK cells, including genes for beta IFN, RI

75 ation studies have shown that an inactivated NDV-LaSota/46 vaccine conferred full protection from NDV

76 sponses to equivalent amounts of inactivated NDV vaccine virus.

77 whether a recombinant attenuated Indonesian NDV strain could provide better protection against preva

78 Interestingly, NDV grown in mammalian cell lines was resistant to compl

79 insertion site of the foreign antigens into NDV that results in enhanced immune responses specific t

80 The incorporation of chicken RCA into NDV produced in embryonated eggs similarly provided spec

81 a virulent Newcastle disease virus isolate (NDV-Peru/08) obtained from poultry during an outbreak of

82 nidase proteins in comparison with all known NDV genotypes, suggesting the existence of an unknown re

83 ed a recombinant NDV-expressing ICOS ligand (NDV-ICOSL).

84 domain of an otherwise non-disulfide-linked NDV HN protein by the introduction of cysteine substitut

85 eal genetic diversity within and among local NDV populations in Africa.

86 ndidate oncolytic NDV based on the mesogenic NDV-73T strain that is no longer classified as a select

87 representing an essential step toward moving NDV forward as an oncolytic agent.

88 Phylogenetic analysis of multiple NDV genotype V representatives revealed that genotype V

89 In contrast to MV, NDV-H induced high levels of type I interferon in plasma

90 between the moderately virulent, neurotropic NDV strain Beaudette C (BC) and the avirulent APMV-2 str

91 Fresh normal human serum (NHS) neutralized NDV by multiple pathways of complement activation, indep

92 d illustrates the continued evolution of new NDV strains in West Africa.

93 In this article, we describe the ability of NDV expressing HIV Gag to generate a Gag-specific immune

94 receptor binding and cleavage activities of NDV HN's site I while activating receptor binding by sit

95 umour models, intratumoral administration of NDV-ICOSL results in enhanced infiltration with activate

96 himeric virus extends the coding capacity of NDV by 30%, suggesting that the two-segmented NDV can be

97 not affect the biological characteristics of NDV.

98 rated the feasibility of aerosol delivery of NDV-vectored vaccines.

99 cell membranes and is a major determinant of NDV pathogenicity.

100 The viral determinants of NDV virulence are not completely understood.

101 plication, while the globular head domain of NDV HN could be replaced with that of APMV-2 with only a

102 evidence that the homologous stalk domain of NDV HN is essential for virus replication, while the glo

103 the transmembrane and cytoplasmic domains of NDV F and HN proteins, respectively, stimulated durable

104 the transmembrane and cytoplasmic domains of NDV F and HN proteins, respectively, were quantitatively

105 ; and APMV-2, containing both ectodomains of NDV.

106 lizing the exceptional oncolytic efficacy of NDV.

107 of the test and to revisit the evolution of NDV in cormorants.

108 riteria for inclusion as a novel genotype of NDV (genotype XVI).

109 these two mutations in the glycoproteins of NDV in the establishment of persistent infection.

110 meric proteins in which the globular head of NDV HN is connected to the stalk region of either human

111 ences are a marker of the natural history of NDV.

112 ribution of each protein to the induction of NDV-specific neutralizing antibodies and protective immu

113 t from all other currently known isolates of NDV, and together, they fulfill the newly established cr

114 ffect of complement on the neutralization of NDV purified from embryonated chicken eggs, a common sou

115 offer new insights into the pathogenesis of NDV infection.

116 ant role in replication and pathogenicity of NDV in vivo.

117 fusion, tropism, and virulence phenotypes of NDV and APMV-2 and that the regions of HN that are criti

118 howed that the two contrasting phenotypes of NDV and APMV-2 could largely be transferred between the

119 We engineered the F protein of NDV and generated a recombinant NDV (rNDV) whose F prote

120 her, the data suggest that the HN protein of NDV is a crucial determinant of thermostability, and the

121 nin-neuraminidase (HN) attachment protein of NDV recognizes sialic acid receptors, whereas the NiV G

122 d colocalization of the HN and M proteins of NDV, indicating that these residues of the HN cytoplasmi

123 and M genes without altering replication of NDV, suggesting that UTRs could be used for enhanced exp

124 Indeed, stalk residues of NDV HN and MV H that likely mediate the F interaction ha

125 We show that the oncolytic selectivity of NDV for tumor cells is dependent upon tumor cell resista

126 esents the first complete genome sequence of NDV in the Dominican Republic.

127 first report of complete genome sequences of NDV strains isolated from chickens in Indonesia.

128 HN and F proteins from another strain of NDV, strain B1, could be incorporated into these VLPs.

129 Many naturally occurring strains of NDV have an intact IFN-antagonistic function and can sti

130 sters are related to genotype VII strains of NDV.

131 uding neurovirulent and avirulent strains of NDV.

132 first comprehensive and systematic study of NDV virulence and pathogenesis.

133 This substitution of NDV F into APMV-2 was sufficient to confer the neurotrop

134 G-F fusion may be more complex than that of NDV HN and F.

135 DVs demonstrated that the thermostability of NDV was dependent on the origin of HN protein.

136 Each virus induced high titers of NDV-specific hemagglutination inhibition and serum neutr

137 of NiV F by NiV G but not the triggering of NDV F by the chimeras.

138 ene probably contributes to the virulence of NDV.

139 fects of N-glycosylation of the F protein on NDV pathobiology and suggest that the N-glycans in HR1 a

140 we have generated a lead candidate oncolytic NDV based on the mesogenic NDV-73T strain that is no lon

141 haracterization of a highly potent oncolytic NDV variant that is unlikely to cause Newcastle disease

142 oser phylogenetic relationship to LBM-origin NDV.

143 ase virus (NDV) isolates from this outbreak (NDV-Belize-3/08, NDV-Belize-4/08, and NDV-Belize-12/08)

144 e (OVCAR3) with a recombinant low-pathogenic NDV, persistent infection was established in a subset of

145 Thus, ND VLPs are a potential NDV vaccine candidate.

146 virus expressing green fluorescent protein (NDV-GFP) from the antiviral effects of interferon (IFN).

147 An additional group of animals received NDV/HA by aerosol administration.

148 cell killing abilities of (i) a recombinant NDV (rNDV) strain, Beaudette C, containing an IFN-antago

149 F protein of NDV and generated a recombinant NDV (rNDV) whose F protein is cleavable exclusively by p

150 We generated a recombinant NDV, designated rLaSota/gp160, expressing the gp160 enve

151 t in the tumour, we engineered a recombinant NDV-expressing ICOS ligand (NDV-ICOSL).

152 Complete recombinant NDV was engineered to express the SARS-CoV spike S glyco

153 rse genetics to develop enhanced recombinant NDV vectors as effective therapeutic agents for cancer t

154 nto the NDV genome by generating recombinant NDV-HIVGag viruses in which HIV gag was located at diffe

155 id not increase the virulence of recombinant NDV (rNDV) strain LaSota.

156 The recombinant NDV selectively replicates in and kills tumor cells and

157 genetically engineered into the recombinant NDV that reduce chicken pathogenicity to a level that is

158 This recombinant NDV has a modification at the fusion protein (F) cleavag

159 ective tumor replication of this recombinant NDV, both in vitro and in vivo, along with efficient tum

160 ne was individually expressed by recombinant NDVs.

161 and pathogenicity, we generated recombinant NDVs with a deletion or point mutation in the N-terminal

162 erved in PVK cells infected with recombinant NDVs expressing the NiV IFN antagonist proteins V and W.

163 The eight recovered NDV HN mutants were assessed for effects on biological a

164 together, two constructs could be recovered: NDV, containing both the F and HN ectodomains of APMV-2;

165 PSA-retargeted NDV efficiently lysed prostasphere tumor mimics, suggest

166 cancer patients with immunosuppression, safe NDV-oncolytic vectors are needed.

167 DV by 30%, suggesting that the two-segmented NDV can be used for development of vaccines or gene ther

168 fibrosarcoma, we show that the IFN-sensitive NDV variants are as effective as IFN-resistant rBC virus

169 Several NDV vaccine vectors have been generated, and their immun

170 However, unlike similar NDV HN and MV H mutants, the NiV G glycosylation stalk m

171 ses and neutralizing antibody responses than NDV-only immunizations.

172 Here we demonstrate that NDV possesses oncolytic activity in tumor cells capable

173 These findings demonstrate that NDV-3 protective efficacy against MRSA in SSSI involves

174 Several studies have demonstrated that NDV is selectively cytotoxic to tumor cells but not norm

175 tudies conducted with chickens revealed that NDV-Peru/08 infection results in clinical signs characte

176 Our results suggest that NDV can be used not only as a cost-effective method for

177 The NDV HN protein exists as a tetramer composed of a pair o

178 The NDV-BC F protein contains six potential acceptor sites f

179 The NDV-DR499-31/08 isolate had an intracerebral pathogenici

180 In addition, the NDV F CT has two conserved tyrosine residues (Y524 and Y

181 V-2 strain Yucaipa (rAPMV-2), containing the NDV F glycoprotein in place of its own.

182 and rAPMV3-HN, were generated expressing the NDV fusion (F) and hemagglutinin-neuraminidase (HN) prot

183 rom the RSV F protein and the other from the NDV F-protein ectodomain (F/HR2F).

184 onclude that these wild-type residues in the NDV F CT have an effect on regulating F protein biologic

185 termined the optimal insertion site into the NDV genome by generating recombinant NDV-HIVGag viruses

186 d cell surface and was incorporated into the NDV virion.

187 Sequence analysis and superposition of the NDV and hPIV-3 HN dimer structures revealed that, simila

188 transmembrane and cytoplasmic domains of the NDV F and HN proteins, respectively, stimulate durable,

189 he specific sequence of the TM domain of the NDV F protein is important for the conformation of the p

190 sed on X-ray crystallographic studies of the NDV HN globular domain, it was proposed that the protein

191 cytoplasmic and transmembrane domains of the NDV HN protein and the ectodomain of the human RSV G pro

192 se results support further evaluation of the NDV-3 vaccine to address disease due to S. aureus in hum

193 To test the NDV model, we have engineered a pair of intermonomeric d

194 These results indicate that the NDV F and HN proteins are independent neutralization and

195 ent transcriptional positions throughout the NDV viral genome.

196 Thus, the NDV F protein can be triggered by binding to the NiV rec

197 ith an RSV F-protein ectodomain fused to the NDV F-protein heptad repeat 2 (HR2), transmembrane, and

198 ein, the Nipah virus G protein, fused to the NDV HN protein cytoplasmic and transmembrane domains was

199 However, the genetic basis underlying the NDV thermostability is poorly understood.

200 s did not form detectable complexes with the NDV hemagglutinin-neuraminidase (HN) protein.

201 NDV could be engineered into a thermolabile NDV vaccine strain for developing novel thermostable NDV

202 ability, and the HN gene from a thermostable NDV could be engineered into a thermolabile NDV vaccine

203 ine strain for developing novel thermostable NDV vaccine.

204 en sera devoid of neutralizing antibodies to NDV were able to effectively neutralize these virions.

205 ults showed that all three strains belong to NDV genotype V and are virulent, as assessed by the intr

206 proteins indicates that receptor binding to NDV HN site II not only can activate its own fusion (F)

207 In contrast to NDV infection, HeV and NiV infection of PVK cells failed

208 tribution of the large polymerase protein to NDV virulence is second only to that of the fusion glyco

209 doxical increase in apoptosis in response to NDV.

210 iently expressed, bind ephrinB2, and trigger NDV F to promote fusion in Vero cells.

211 iV F by the G protein and that of triggering NDV F by the chimeras can be distinguished by differenti

212 The complete genome sequences of two NDV strains and the sequences of the surface protein gen

213 inguish this isolate from viruses of typical NDV genotypes.

214 suggesting that another mechanism underlies NDV's tumor specificity.

215 e data illustrate that it is feasible to use NDV as a vaccine vector to elicit potent humoral and muc

216 ring 2009-2010, despite intense vaccination, NDV caused major outbreaks among commercial poultry farm

217 A) protein, and we showed that this vaccine (NDV/HA) induced a high level of HPAIV-specific mucosal a

218 ge and complete protection against velogenic NDV challenge.

219 otection against virulent ILTV and velogenic NDV challenges.

220 irst complete characterization of a virulent NDV isolate from South America.

221 nferred complete protection against virulent NDV challenge.

222 erse genetics system for the highly virulent NDV strain Banjarmasin/010/10 (Ban/010) isolated in Indo

223 strain, LaSota, and an intermediate virulent NDV strain, Beaudette C (BC), and the N and P genes were

224 947 ancestral viruses suggests that virulent NDV strains may have evolved in unknown reservoirs in th

225 and mortality after challenge with virulent NDV strain Ban/010 (genotype VII) or GB Texas (genotype

226 immunized birds 21 days later with virulent NDV via the oculonasal, intramuscular, or intravenous ro

227 irus infection with Newcastle disease virus (NDV) after a 24-hour E2 treatment.

228 P and M proteins of Newcastle disease virus (NDV) and a chimeric protein containing the cytoplasmic a

229 ion (F) proteins of Newcastle disease virus (NDV) and Nipah virus (NiV) are both triggered by binding

230 ein induced by both Newcastle disease virus (NDV) and Sendai virus infections, without targeting it f

231 , we have evaluated Newcastle disease virus (NDV) as a vaccine vector for norovirus.

232 onses by the use of Newcastle disease virus (NDV) as a vaccine vector.

233 mesogenic strain of Newcastle disease virus (NDV) as an oncolytic agent for cancer therapy has been h

234 Newcastle disease virus (NDV) belongs to serotype 1 of the avian paramyxoviruses

235 Newcastle disease virus (NDV) can cause severe disease in chickens.

236 Virulent strains of Newcastle disease virus (NDV) cause Newcastle disease (ND), a devastating disease

237 (VLPs) built on the Newcastle disease virus (NDV) core proteins, NP and M, and containing two chimeri

238 LPs) containing the Newcastle disease virus (NDV) core proteins, NP and M, and two chimera proteins (

239 MPORTANCE Oncolytic Newcastle disease virus (NDV) could establish persistent infection in a tumor cel

240 Newcastle disease virus (NDV) entry into host cells is mediated by the hemaggluti

241 Newcastle disease virus (NDV) expressing HIV-1 BaL gp160 was evaluated either alo

242 rated a recombinant Newcastle disease virus (NDV) expressing the MV hemagglutinin (NDV-H).

243 Newcastle disease virus (NDV) fusion (F) protein directs membrane fusion, which i

244 rane (TM) domain of Newcastle disease virus (NDV) fusion (F) protein in the structure and function of

245 lycosylation of the Newcastle disease virus (NDV) fusion (F) protein in viral replication and pathoge

246 The Newcastle disease virus (NDV) fusion protein (F) mediates fusion of viral and hos

247 ccurring strains of Newcastle disease virus (NDV) have shown oncolytic therapeutic efficacy in precli

248 active sites on the Newcastle disease virus (NDV) hemagglutinin-neuraminidase (HN) and measles virus

249 site identified in Newcastle disease virus (NDV) HN.

250 involving virulent Newcastle disease virus (NDV) in wild double-crested cormorants (Phalacrocorax au

251 ase (HN) protein of Newcastle disease virus (NDV) is a multifunctional protein that plays a crucial r

252 Newcastle disease virus (NDV) is a negative-sense RNA virus that has been shown t

253 Newcastle disease virus (NDV) is an oncolytic virus being developed for the treat

254 s of three virulent Newcastle disease virus (NDV) isolates from this outbreak (NDV-Belize-3/08, NDV-B

255 LPs composed of the Newcastle disease virus (NDV) nucleocapsid and membrane proteins and chimera prot

256 isease is caused by Newcastle disease virus (NDV) or avian paramyxovirus type 1 (APMV-1), a negative-

257 A Newcastle disease virus (NDV) outbreak in chickens was reported in the Dominican

258 rated a recombinant Newcastle disease virus (NDV) possessing a two-segmented genome.

259 study, we generated Newcastle disease virus (NDV) recombinants expressing glycoproteins B (gB) and D

260 study, we generated Newcastle disease virus (NDV) recombinants, based on the LaSota vaccine strain, e

261 cytoplasmic tail in Newcastle disease virus (NDV) replication and pathogenicity, we generated recombi

262 membrane fusion by Newcastle disease virus (NDV) requires an interaction between the viral hemagglut

263 ells expressing the Newcastle disease virus (NDV) strain AV proteins NP, M, HN (hemagglutinin-neurami

264 uence of an African Newcastle disease virus (NDV) strain isolated from a chicken in Togo in 2009 was

265 is known about the Newcastle disease virus (NDV) strains circulating in African countries.

266 Naturally occurring Newcastle disease virus (NDV) strains vary greatly in virulence, ranging from no

267 Naturally occurring Newcastle disease virus (NDV) strains vary greatly in virulence.

268 ght highly virulent Newcastle disease virus (NDV) strains were isolated from vaccinated commercial ch

269 Thermostable Newcastle disease virus (NDV) vaccines have been used widely to protect village c

270 rated a recombinant Newcastle disease virus (NDV) vectoring the fusion (F) protein and glycoprotein (

271 Newcastle disease virus (NDV) was isolated from an outbreak in layer chickens in

272 nd pathogenicity of Newcastle disease virus (NDV), a green fluorescent protein (GFP) gene flanked by

273 dney (PVK) cells to Newcastle disease virus (NDV), an avian paramyxovirus known to elicit a strong in

274 eviously engineered Newcastle disease virus (NDV), an avian paramyxovirus, as a vector to express the

275 Newcastle disease virus (NDV), an avian paramyxovirus, is a promising OV and is i

276 Newcastle disease virus (NDV), an avian paramyxovirus, is inherently tumor select

277 Newcastle disease virus (NDV), an avian paramyxovirus, is tumor selective and int

278 SV), Sindbis virus, Newcastle disease virus (NDV), and Sendai virus (SeV), was significantly inhibite

279 movirus (aMPV), and Newcastle disease virus (NDV), human pathogens such as human respiratory syncytia

280 umoral therapy with Newcastle disease virus (NDV), in addition to the activation of innate immunity,

281 When infected with Newcastle Disease Virus (NDV), NOD2 expression in DCs was induced about four-fold

282 For Newcastle disease virus (NDV), one bifunctional site (site I) on HN's globular he

283 virulent strains of Newcastle disease virus (NDV), representing avian paramyxovirus serotype 1 (APMV-

284 e I IFN response to Newcastle disease virus (NDV), Sendai virus (SeV), and Semliki Forest virus (SFV)

285 and pathogenesis of Newcastle disease virus (NDV), we generated recombinant viruses with deletions in

286 lls infected with a Newcastle disease virus (NDV)-expressing VP35 redistributed DRBP76 from the nucle

287 Newcastle disease virus (NDV)-induced membrane fusion requires an interaction bet

288 Newcastle disease virus (NDV)-induced membrane fusion requires formation of a com

289 study, we show that Newcastle disease virus (NDV)-vectored H7 (NDV-H7) and NDV-H5 vaccines are able t

290 in humans, such as Newcastle disease virus (NDV).

291 The three vaccine viruses [NDV/HA, NDV/HA(RV), and NDV/NA] were administered separa

292 behaved as a typical velogenic viscerotropic NDV strain, causing severe necrohemorrhagic lesions in t

293 ns characteristic of velogenic viscerotropic NDV strains.

294 In cotton rats immunized with NDV-H, neutralizing antibodies were also generated in th

295 To avoid potential toxicity issues with NDV, especially in cancer patients with immunosuppressio

296 ivo, coapplication of UV-inactivated MV with NDV led to increased MV-specific antibody production in

297 exhibited resistance to superinfection with NDV and established an antiviral state, as demonstrated

298 encouraging phase I/II clinical trials with NDV, further refinements for tumor-specific targeting ar

299 Chickens were immunized with NDVs expressing a single antigen (HA, NA, and M2), two a

300 n Mexico, clustering into a new clade within NDV subgenotype Vb.